Bright Minds Biosciences Inc. (CSE:DRUG)
Canada · Delayed Price · Currency is CAD | Market Cap | 1.09B +165.1% |
| Revenue (ttm) | n/a |
| Net Income | -19.84M |
| EPS | -2.73 |
| Shares Out | 9.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 514 |
| Average Volume | 537 |
| Open | 115.70 |
| Previous Close | 118.20 |
| Day's Range | 111.03 - 115.71 |
| 52-Week Range | 33.01 - 170.00 |
| Beta | -0.49 |
| RSI | 47.86 |
| Earnings Date | Feb 10, 2026 |
About Bright Minds Biosciences
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neurop... [Read more]
Financial Performance
Financial StatementsNews
Bright Minds Biosciences to Present at Upcoming Conferences
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 ag...
BTIG Maintains Buy Rating for Bright Minds Biosciences (DRUG) with $147 Target | DRUG Stock News
BTIG Maintains Buy Rating for Bright Minds Biosciences (DRUG) with $147 Target | DRUG Stock News
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) today closed its recently announced public offering of 1,945,000 ...
Bright Minds Biosciences (DRUG) Prices $175M Public Offering
Bright Minds Biosciences (DRUG) Prices $175M Public Offering
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the pricing of its previously announced public offering...
Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating
Bright Minds Biosciences remains a "Strong Buy" after positive phase 2 data for BMB-101 in drug-resistant epilepsies. DRUG's BMB-101 achieved -73.1% and -63.3% median seizure reductions in Absence Epi...
Bright Minds Biosciences, Praxis Precision Medicines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Full story available on Benzinga.com
Bright Minds Biosciences launches $100 million public offering
Bright Minds Biosciences Announces Launch of US$100 Million Public Offering
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the launch of a public offering of common shares in the...
BTIG Raises Price Target for Bright Minds Biosciences (DRUG) to $147 | DRUG Stock News
BTIG Raises Price Target for Bright Minds Biosciences (DRUG) to $147 | DRUG Stock News
Bright Minds Biosciences Inc BMB-101 Topline data announcement Transcript
Bright Minds Biosciences Inc BMB-101 Topline data announcement Transcript
New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday
Bright Minds Biosciences Inc. (NASDAQ: DRUG) stock is trading higher on Tuesday after the company shared topline results from its Phase 2 BREAKTHROUGH trial of BMB-101 for drug-resistant Absence Seizu...
Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Tuesday. Shares of Microchip Technology Inc (NASDAQ: MCHP) rose sharply during Tuesday's session after the semiconduc...
Bright Minds Biosciences (DRUG) Surges on Successful Trial Results
Bright Minds Biosciences (DRUG) Surges on Successful Trial Results
Bright Minds gains on mid-stage trial win for lead asset
Bright Minds Biosciences (DRUG) stock jumps as lead drug BMB-101 succeeds in a mid-stage trial against a severe neurological disease. Read more here.
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright Minds” or the “Company”), a clinical-stage biotechnology company focused on developing hig...
Bright Minds To Unveil Topline Results For BMB-101 Phase 2 Trial In Absence Seizures And DEE
(RTTNews) - Bright Minds Biosciences Inc. (DRUG), a clinical-stage biotechnology company, announced that it will host a conference call and live webcast at 8:00 AM ET on January 6, 2026, to report top...
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026
– Conference Call and Live Webcast at 8AM ET – NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright Minds” or the “Company”), a clinical-stage ...
Bright Minds Biosciences (DRUG) Maintains Buy Rating with $80 Price Target | DRUG Stock News
Bright Minds Biosciences (DRUG) Maintains Buy Rating with $80 Price Target | DRUG Stock News
Bright Minds Biosciences (DRUG) Sees Stable Analyst Rating Today | DRUG Stock News
Bright Minds Biosciences (DRUG) Sees Stable Analyst Rating Today | DRUG Stock News
Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting
NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 ag...
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is qu...
Why Bright Minds Biosciences Stock Topped the Market on Monday
The company isn't wasting any time drafting seasoned professionals to help it develop medication for a rare genetic disorder.
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)
-- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; distinguished global experts in PWS, will support the Company's PWS program, which w...
Sio Capital Management, LLC Reduces Stake in Bright Minds Biosciences Inc
Sio Capital Management, LLC Reduces Stake in Bright Minds Biosciences Inc